The British In Vitro Diagnostics Association (BIVDA) has released new three-year strategy, ‘Diagnostics for All’
The British In Vitro Diagnostics Association (BIVDA) have released new three-year strategy, ‘Diagnostics for All’.
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Apr 24
The British In Vitro Diagnostics Association (BIVDA) have released new three-year strategy, ‘Diagnostics for All’.
17 Apr 24
Manufactured by Alvotech, Selarsdi is the second biosimilar approved under the strategic partnership between Alvotech and Teva, for…
17 Apr 24
Beckman Coulter Diagnostics, a leader in clinical diagnostics, announced today, ahead of the congress of the European Society…
17 Apr 24
Medincell and AbbVie will co-develop up to six LAI therapeutic products whereas AbbVie will provide funding, manage the…
17 Apr 24
The approval was based on findings from three clinical studies that demonstrated Nulibry's safety and effectiveness in MoCD…
17 Apr 24
According to the results, Imfinzi along with chemotherapy decreased the mortality risk by 26% versus chemotherapy alone at…
17 Apr 24
P95, a leading global provider of clinical and epidemiology services focused on vaccines and infectious diseases, has opened…
17 Apr 24
Vaccine candidate provides broad coverage against the five most common groups of bacteria causing invasive meningococcal disease and…
17 Apr 24
CSafe, an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, proudly announces the launch of…
17 Apr 24
On Apr. 11, 2024, VITAL HealthCare, one of the 5 core business divisions of the VITAL Group, marked a stunning…